Neurologybytes Academy

Marrie RA. Clin Invest Med 2019;42:E5–E12.
Chalah MA, et al. Braz J Psychiatry 2017;39:365–8.
Marrie RA, et al. Mult Scler 2015;21:263–81.
Boeschoten RE, et al. J Neurol Sci 2017;372:331–42.
Patten SB, et al. Int Rev Psychiatry 2017;29:463–72.
Butler E, et al. Mult Scler Relat Disord 2016;10:145–68.
Gilberthorpe TG, et al. Neuropsychiatr Dis Treat 2017;3:303–18.
Chwastiak LA, Ehde DM. Psychiatr Clin North Am 2007;30:803–17.
Lim GY, et al. Sci Rep 2018;8;2861.
Baxter AJ, et al. Psychol Med 2013;43:897–910.
Remes O, et al. Brain Behav 2016;6:e00497.
Marrie RA, et al. Neurology 2009;72:117–24.
Fiest KM, et al. Int J MS Care 2016;18:96–104.
Marrie RA. Nat Rev Neurology 2017;13:375–82.
Lobentanz IS. Acta Neurol Scand 2004;111:6–13.
McKay KA, et al. Neurology 2018;90:e1316–23.
Thormann A, et al. Neurology 2017;89:1668–75.
Reynolds CF, et al. Ann Rev Public Health 2012;33:123–35.
Patten SB, et al. Mult Scler 2000;6:115–20.
Sparaco M, et al. J Neurology. 2019;doi: 10.1007/s00415-019-09426-6 [Epub ahead of print].
Zhang T, et al. Neurology 2016;86:1287–95.
Iaffaldano P. Mult Scler 2018;24:(S2):8–120 [Abstract 204].
DiMatteo MR, et al. Arch Intern Med 2000;160:2101–7.
Higuera L, et al. J Manag Care Spec Pharm 2016;22:1394–401.
Morrow SA, et al. J Affect Disord 2015;187:142–6.
Palé AL, et al. Mult Scler Relat Disord 2017;17:138–43.
Schippling S, et al. J Neurol 2016;263:1418–26.
Gasim M, et al. Mult Scler Relat Disord 2018;26:124–56.
Sørensen P, et al. Mult Scler 2019;25:627–36.
Roman C, et al. J Am Assoc Nurse Pract 2017;29:629–38.
Dougados M, et al. Ann Rheum Dis 2015;74:1725–33.

Tim

Current medication

Previous clinical history

Recently developed symptoms

Tim

Current medication

Previous clinical history

Recently developed symptoms

What percentage of patients with MS and the general population experience depression and anxiety?

How can comorbidities such as depression and anxiety affect patients with MS?

Select all that apply

What does the physician need to consider when treating a MS patient with depression or anxiety?

Select the right answer(s)

What are the suggested elements of the MS care team?

Select all that apply

Mental health and MS: Providing evidence-based support

Please note you are now leaving Neurologybytes.com and being redirected to a different website not operated by Teva Pharmaceuticals.

Please rotate your device to landscape

For the best learning experience, we recommend to use a desktop device.

Mental health and MS: Providing evidence-based support

Learning objectives

Case study of a patient with recent change in symptoms

Tim

Current medication

Previous clinical history

Recently developed symptoms

Based on Tim’s symptom profile, what would your next steps be?

Select all that apply

Case study of a patient with recent change in symptoms

Tim

Current medication

Previous clinical history

Recently developed symptoms

Given his symptoms, do you think Tim should be assessed for depression using one of the scales discussed?

What percentage of patients with MS and the general population experience depression and anxiety?

How can comorbidities such as depression and anxiety affect patients with MS?

Select all that apply

What does the physician need to consider when treating a MS patient with depression or anxiety?

Select the right answer(s)

What are the suggested elements of the MS care team?

Select all that apply

Congratulations!

You have completed module 3

Mental health and MS: Providing evidence-based support

Exercise in people with MS: What recommendations can we give?

Considering the complete patient when talking about family planning

Mental health and MS:
Providing evidence-based support